Reuters Health News Summary devdiscourse.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from devdiscourse.com Daily Mail and Mail on Sunday newspapers.
The approvals, third line for BMS and 2seventy Bio’s Abecma and second line for J&J and Legend Biotech’s Carvykti, represent a new class of therapy for these blood cancer patients.
J&J wins FDA nod for Carvykti label expansion (NYSE:JNJ) seekingalpha.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from seekingalpha.com Daily Mail and Mail on Sunday newspapers.
The decision comes after a panel of expert advisers voted in favor of Abecma's use as an earlier treatment for multiple myeloma, a common form of cancer that affects older adults. The cell therapy is already approved in the U.S. to treat patients with multiple myeloma who have received four or more prior lines of treatment.
China Universal Asset Management Co. Ltd. boosted its holdings in shares of Legend Biotech Co. (NASDAQ:LEGN – Free Report) by 350.3% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 9,222 shares of the company’s stock after purchasing an additional 7,174 […]